chronic spontaneous urticaria
Immunology · 2016–2026
4decisions
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| omalizumab Treatment of uncontrolled severe asthma (USA), uncontrolled severe allergic asthma (USAA), and severe chronic spontaneous urticaria (CSU) in eligible patients.… | Mar 2026 | Recommended with restriction | no section in document |
| omalizumab New formulations (pre-filled pen and pre-filled syringe with safety device) and new 300 mg/2 mL strength of omalizumab for the treatment of uncontrolled severe… | Mar 2025 | Recommended with restriction | input received Asthma Australia · National Allergy Council · Anaphylaxis Australia |
| omalizumab Severe chronic spontaneous urticaria (CSU) in patients who have failed to achieve adequate response to standard therapy with H1 antihistamines combined with… | Mar 2018 | Recommended with restriction | none received |
| omalizumab Treatment of chronic spontaneous urticaria (CSU) in patients with severe disease who remain symptomatic despite treatment with H1-receptor antagonists. | Nov 2016 | Recommended | none received |
Who spoke
Asthma Australia · National Allergy Council · Anaphylaxis Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.